2型糖尿病三种治疗方案的成本-效果分析

Cost-EffectivenessAnalysis of 3 Therapeutic Schemes in the Treatment of Type2 Diabetes

目的:评价我院三种治疗2型糖尿病方法的临床疗效及经济成本。方法:选择我院273例2型糖尿病患者,随机分为三组,实施三种联合用药治疗方案。A组二甲双胍+格列本脲,B组二甲双胍+阿卡波糖,C组阿卡波糖+瑞格列奈;定期对各组患者的血糖水平进行监测,经过6个月的治疗,进行经济效果、不良反应及药物疗效分析。结果:三组在治疗后的FPG、PGB、HbA1c均得到较理想的控制。A、B、C组总有效率分别为82.4%,84.6%和85.7%(P>0.05)无显著性差异;A、B、C、组成本-效果比(C/E)分别为1.376、16.276和23.733,B、C组对于A组的增量成本-效果比(△C/△E)分别为74.36和582.0。结论:各组治疗2型糖尿病的用药方案疗效均较好,但从经济成本及总有效率等方面综合考虑,二甲双胍+格列本脲方案为较佳选择。

Objective：To evaluate the clinical and economic effects of three hypoglycemic drugs for type 2 diabetes.Methods：273 cases of type 2 diabetes were randomly divided into 3 groups,each group 91 persons.Group A was treated by Metformin combined with Glibenclamide;Group B was treated by Metformin combined with Acarbose;Group C was treated by Acarbose combined with Repaglinide.The blood glucose level of patients in each group was regularly monitored.The economic effectiveness,adverse reactions,and medication effects were analyzed before treatment and after 6 months treatment.Results：The FPG,PBG and HbA1c of three groups were ideally controlled.The total effective rates of group A,B and C were 82.4%,84.6% and 85.7%,respectively（P0.05）.The cost-effect ratio of group A、B、C is respectively：1.376、16.276 and 23.733.The overrun cost-effect ratio of group B、C to group A is 574.36 and 582.0,respectively.Conclusion：The three groups of treatment of type 2 diabetes have better efficacy of the program.However,considering from cost and total effective rate,the scheme Metformin combined with Glibenclamide is the better choice.